Most Men Choose Active Surveillance for Low-Risk Prostate Cancer
22 Jan 2024
Clinical Result
MONDAY, Jan. 22, 2024 -- More than half of newly diagnosed patients with low-risk prostate cancer (LRPC) chose active surveillance (AS), with recommendation from a urologist being the strongest determinant of AS uptake, according to a study published online Jan. 22 in Cancer.
Jinping Xu, M.D., from the Wayne State University School of Medicine in Detroit, and colleagues examined factors influencing AS uptake in a survey administered to Black and White newly diagnosed patients with LRPC who were aged 75 years or older. Data were included for 1,688 participants identified through metro‐Detroit and Georgia population‐based cancer registries.
The researchers found that 57 percent of the study participants chose AS over definitive treatment (51 and 61 percent of Black and White participants, respectively). Older age, White race, and higher education were patient factors associated with initial AS uptake in an unadjusted analysis. None of these factors were significant predictors of AS uptake after adjustment for covariates. AS recommendation by a urologist was the strongest determinant of AS uptake (adjusted prevalence ratio, 6.59). Shared patient-physician treatment decision, greater prostate cancer knowledge, and residence in metro‐Detroit compared with Georgia were other factors associated with the decision to undergo AS. The likelihood of choosing AS was lower for men whose decision was strongly influenced by the desire to achieve "cure" or "live longer" with treatment and those who perceived their LRPC diagnosis as more serious.
"This indicates that patient perceptions and acceptance of AS have improved over time, although geographical and racial differences in uptake remain," the authors write.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Posted January 2024
More news resources
FDA Medwatch Drug Alerts
Daily MedNews
News for Health Professionals
New Drug Approvals
New Drug Applications
Drug Shortages
Clinical Trial Results
Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.